1Morley JE. Diabetes and aging;Epidemiologic overview. Clin Geriatr Med 2008;24:395 -405.
2Use of Glycated Haemoglobin ( HbA1 c ) in the Diagnosis of Diabetes MeUitus, Abbreviated Report of a WHO Consultation,20111. Stumvoll M, Hing H-U, Matthaei S. Metformin. Endocr Res 2007 ; 32:39 - 57.
3Holman RR,Paul SK,Bethel MA,et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008 ; 359 : 1577 - 89.
4Li D, Yeung SC, Hassan MM, Konopleva M & Abbruzzese JL. Antidiabetic therapies affect risk of pancreatic cancer. Gastrcenterol 2009 ; 137:482 - 488.
5Matthew C, Robert C, Aaron S, et al. The prevalence of vita- min B12 Deficiency in patients with type 2 diabetes;a cross sectional study. J Am Board Fam Med 2009;22:528 -534.
6Piccinni C, Motola D,Marchesini G, et al. Assessing the asso- ciation of pioglitazone use and bladder cancer through drug adverse e- vent reporting. Diabetes Care 2011 ;doi 10.2337/dc102412.
7Van de Laar FA, Lucassen PL, Akkermans RP, et al. Alpha- glucosdase inhibitors for patients with type 2 diabetes;results from a Cochrane systematic review and meta-analysis. Diabetes Care 2005 ; 28:154 - 163.
9Drucker DJ. Dipeptidyl peptidase-4 inhibition and the treat- ment of type 2 diabetes. Preclinical biology and mechanism of action. Diabetes Care 2007 ;30 : 1335 - 1343.
1Hu D,Xie J,Fu P,et al.Central rather than overall obesity is related to diabetes in the Chinese population:.the InterASIA study.Obesity (Silver Spring),2007,15:2809-2816.
2Pan C,Yang W,Jia W,et al.Management of Chinese patients with type 2 diabetes,1998-2006:the Diabcare-China surveys.Curr Med Res Opin,2009,25:39-45.
3Raskin P,Allen E,Hollander P,et al.Initiating insulin therapy in type 2 diabetes:a comparison of biphasic and basal insulin analogs.Diabetes Care,2005,28:260-265.
4Yang W,Ji Q,Zhu D,et al.Biphasic insulin aspart 30 three times daily is more effective than a twice-daily regimen,without increasing hypoglycemia,in Chinese subjects with type 2 diabetes inadequately controlled on oral antidiabetes drugs.Diabetes Care,2008,31:852-856.
5Concato J,Shah N,Horwitz RI.Randomized,controlled trials,observational studies,and the hierarchy of research designs.N Engl J Med,2000,342:1887-1892.
6Whiting DR, Guariguata L, Weil C, et al. IDF diabetes atlas : global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract, 2011,94:311-321.
7Rossi MC, Nico|ucci A. Liraglutide in type 2 diabetes: from parmacological development to clinical practice. Acta Biomed, 2009, 80:93-101.
8Dharmalingam M, Sriram U, Baruah MP. Liraglutide: A review of its therapeutic use as a once daily GLP-1 analog for the management of type 2 diabetes mellitus. Indian J Endocrinol and Metab, 2011,15:9-17.
9Gautier JF, Choukem SP, Girard J. Physiology of ineretins ( GIP and GLP-1 ) and abnormalities in type 2 diabetes. Diabetes Metab, 2008, 34 ( Suppl 2) : $65-$72.
10Marre M, Shaw J, Br/indle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes ( LEAD- 1 SU). Diabet Med, 2009,26:268-278.
